Else Nutrition Reports 2025 First Quarter Financial Results and Provides Business Update

Executive Summary

• Else Nutrition Holdings Inc. reported financial results for the first quarter ended March 31, 2025, highlighting a significant improvement in profitability metrics despite flat revenue.
• The company achieved a gross profit margin increase to 25% (up from 8% in Q1 2024) driven by a 48% reduction in operating expenses.
• Management outlined strategic shifts, including a planned move to powder formula manufacturing in Europe to reduce costs and mitigate supply chain risks, alongside regulatory efforts to expand access to plant-based infant nutrition.

Key Details

• Revenue: $2.1 million CAD for Q1 2025, unchanged from Q1 2024.
• Operating Expenses: $2.2 million CAD for Q1 2025, a 48% decrease from $4.2 million CAD in Q1 2024.
• Gross Profit: Increased to $0.5 million CAD in Q1 2025, compared to $0.18 million CAD in Q1 2024.
• Gross Profit Margin: Improved to 25% in Q1 2025, up from 8% in Q1 2024.
• Cash Position: $0.2 million CAD (including restricted cash) as of March 31, 2025.
• Strategic Initiatives:
  • Planned shift toward manufacturing powder formulas in Europe to lower production costs, improve margins, and control inventory/logistics.
  • Geographic diversification aimed at mitigating supply chain risks and navigating tariffs.
  • Reevaluation of retail distribution model to focus on higher-potential partnerships and a data-driven go-to-market approach.
• Regulatory Updates:
  • Advancement of "Operation Stork Speed" and the FY2026 Agriculture Appropriations Bill to modernize U.S. policy on infant formula.
  • Efforts to streamline FDA approval pathways for clean-label, non-dairy, non-soy alternatives.
  • Optimism regarding clinical trials for infant formula products.
• Future Outlook: Focus on deepening retail partnerships, expanding global manufacturing, and exploring strategic collaborations to accelerate scale.

Notable Quotes

• "As we entered 2025, we continued reshaping Else Nutrition—implementing strategic changes essential to long-term success... We held revenue steady while significantly reducing operating expenses and driving a sharp improvement in gross profit." — Hamutal Yitzhak, CEO & Co-Founder
• "Operationally, a major milestone is our planned shift toward manufacturing powder formulas in Europe. This initiative will allow us to reduce production costs, improve gross margins, and better control inventory and logistics." — Hamutal Yitzhak, CEO & Co-Founder